These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25939173)

  • 1. PCSK9 inhibitors on the way.
    Patel KR
    Manag Care; 2014 Nov; 23(11):43. PubMed ID: 25939173
    [No Abstract]   [Full Text] [Related]  

  • 2. New class PCSK9 blockers stride into cholesterol market.
    Sheridan C
    Nat Biotechnol; 2015 Aug; 33(8):785-6. PubMed ID: 26252118
    [No Abstract]   [Full Text] [Related]  

  • 3. PCSK9 Inhibitors May Show Benefits of Ultra-Low LDL Levels.
    Reinke T
    Manag Care; 2015 Aug; 24(8):13-4. PubMed ID: 26399135
    [No Abstract]   [Full Text] [Related]  

  • 4. [PCSK9 inhibitors: emerging treatment to lower cholesterol?].
    Gencer B; Rodondi N; Mach F
    Rev Med Suisse; 2014 Mar; 10(420):539-42, 544. PubMed ID: 24701672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PCSK9: is this the way forward for managing residual risk?
    Chowdhury SR; Rees A
    Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
    [No Abstract]   [Full Text] [Related]  

  • 6. New therapeutic principles for Familial Hypercholesterolemia.
    Norata GD
    Clin Biochem; 2014 Jun; 47(9):756. PubMed ID: 24854692
    [No Abstract]   [Full Text] [Related]  

  • 7. The promises of PCSK9 inhibition.
    Petrides F; Shearston K; Chatelais M; Guilbaud F; Meilhac O; Lambert G
    Curr Opin Lipidol; 2013 Aug; 24(4):307-12. PubMed ID: 23817198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges.
    Norata GD; Tibolla G; Catapano AL
    Vascul Pharmacol; 2014 Aug; 62(2):103-11. PubMed ID: 24924410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H; Melone M; Rashid S
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update of Clinical Trials of Anti-PCSK9 Antibodies.
    Wu NQ; Li S; Li JJ
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial hypercholesterolaemia: PCSK9 inhibitors are coming.
    Santos RD; Watts GF
    Lancet; 2015 Jan; 385(9965):307-10. PubMed ID: 25282517
    [No Abstract]   [Full Text] [Related]  

  • 13. Cholesterol-lowering blockbuster candidates speed into Phase III trials.
    Mullard A
    Nat Rev Drug Discov; 2012 Nov; 11(11):817-9. PubMed ID: 23123928
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-PCSK9 therapies for the treatment of hypercholesterolemia.
    Hooper AJ; Burnett JR
    Expert Opin Biol Ther; 2013 Mar; 13(3):429-35. PubMed ID: 23240807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics. Simple genetics for a complex disease.
    Cohen JC; Hobbs HH
    Science; 2013 May; 340(6133):689-90. PubMed ID: 23661745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finding the Right Price for Improving Care.
    Charlton B
    JAMA Intern Med; 2016 Jan; 176(1):109. PubMed ID: 26662340
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels.
    Steinberg D; Witztum JL
    Proc Natl Acad Sci U S A; 2009 Jun; 106(24):9546-7. PubMed ID: 19506257
    [No Abstract]   [Full Text] [Related]  

  • 20. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.